# EDGAR Filing Document

**Accession Number:** 0001801834
**File Stem:** 0000000000-26-005074
**Filing Date:** 2026-5
**Character Count:** 2314
**Document Hash:** 54d2d51798d5f6555c0a3bfab31f266b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-005074.hdr.sgml**: 20260702

**ACCESSION NUMBER**: 0000000000-26-005074

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260518

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PRF Technologies Ltd.
- **CENTRAL INDEX KEY:** 0001801834
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-295841

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 65 YIGAL ALON ST.
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 972-3-7177051

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 65 YIGAL ALON ST.
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAINREFORM LTD.
- **DATE OF NAME CHANGE:** 20200131
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001178913-26-002645

## Text-Extract

```

                                                            May 18, 2026

Efraim Cohen-Arazi
Interim Chief Executive Officer
PRF Technologies Ltd.
65 Yigal Alon St.
Tel Aviv 6744316, Israel

        Re: PRF Technologies Ltd.
            Registration Statement on Form F-1
            Filed May 13, 2026
            File No. 333-295841
Dear Efraim Cohen-Arazi:
       This is to advise you that we have not reviewed and will not review your
registration
statement.
       Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you that
the company and its management are responsible for the accuracy and adequacy of
their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:    Michael Soumas, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._